1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Valeant shares soar after sale of its iNova Business

Discussion in 'Valeant Pharmaceuticals' started by RobertPhillips900, Sep 29, 2017 at 2:36 PM.

  1. RobertPhillips900

    Aug 29, 2016
    Likes Received:
    Valeant completed the sale of its iNova Pharmaceuticals business for $930MM in cash. The pharma company intends to use the net proceeds from the sale to repay term loan debt under its Senior Credit Facility. http://alph.st/bf137c6c

  2. anonymous

    anonymous Guest

    Shit, I thought they would use it on R&D
  3. anonymous

    anonymous Guest

    LOL. Agree that they should build up their pipeline for future growth since they ain't going to grow by acquisition anymore.

    IMHO, they're going to give everyone on the executive team a chunk of the proceeds for a job well done.

    Selling iNova also sold off that revenue stream, no real dent to the debt covenant ratios. Debt due in 2020 will need to be refinanced in 2019 at higher rates, so interest expense will not go down.
  4. anonymous

    anonymous Guest

    I wouldn't say soar, Phillip Morris.
  5. anonymous

    anonymous Guest

    He means sour.